WHO ICTRP trial
Phase 3 Study of ASP2151 in Herpes Zoster Patients - A…
JPRN-jRCT2080222242 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080222242 |
|---|---|
| Public title | Phase 3 Study of ASP2151 in Herpes Zoster Patients - A Double-blind,Valaciclovir-controlled Study - |
| Scientific title | Phase 3 Study of ASP2151 in Herpes Zoster Patients - A Double-blind,Valaciclovir-controlled Study - |
| Primary sponsor | Maruho Co.,Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | herpes zoster |
| Interventions | investigational material(s) Generic name etc : ASP2151 INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational material : 200 mg once daily or 400 mg once daily… |
| Registration date | Feb 10, 2013 |
| Target size | 750 |
| Secondary IDs | JapicCTI-132291 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: